In vitro cell based cytotoxicity and T cell activation assays to assess safety and efficacy of engineered T cell therapies

被引：0
|
作者：
Holt, Sanne [1 ]
Vermond, Sophie [1 ]
Hazenoot, Monique Hazenoot [1 ]
Overman, Jeroen [1 ]
Aarbiou, Jamil Aarbiou [1 ]
DeGroot, Jeroen DeGroot [1 ]
机构：
[1] Charles River Labs, Leiden, Netherlands
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-3232
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3232
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Engineered T Cell Therapies from a Drug Development Viewpoint
    Chen, Fang
    Fraietta, Joseph A.
    June, Carl H.
    Xu, Zhongwei
    Melenhorst, J. Joseph
    Lacey, Simon F.
    [J]. ENGINEERING, 2019, 5 (01) : 140 - 149
  • [32] Colorimetric In Vitro Evaluation of T-Cell Cytotoxicity
    L. M. Khromykh
    T. V. Anfalova
    D. B. Kazanskii
    [J]. Bulletin of Experimental Biology and Medicine, 2003, 136 : 314 - 317
  • [33] Colorimetric in vitro evaluation of T-cell cytotoxicity
    Khromykh, LM
    Anfalova, TV
    Kazanskii, DB
    [J]. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2003, 136 (03) : 314 - 317
  • [34] T-cell therapies for T-cell lymphoma
    Toner, Keri
    Bollard, Catherine M.
    Dave, Hema
    [J]. CYTOTHERAPY, 2019, 21 (09) : 935 - 942
  • [35] Multiplexed TCR-T Cell Therapy: A Strategy to Enhance the Efficacy of Engineered T Cell Therapy
    Wang, Yifan
    Tadros, Jenny
    Nabilsi, Nancy
    Ferretti, Andrew
    Nguyen, Dalena
    Traore, Tary
    Virbasius, Amy
    Xu, Qikai
    Gurer, Cagan
    MacBeath, Gavin
    [J]. MOLECULAR THERAPY, 2022, 30 (04) : 510 - 511
  • [36] Improved T Cell activation bioassays to advance the development of bispecific antibodies and engineered T cell immunotherapies
    Somberg, Richard L.
    Stecha, Pete
    Garvin, Denise
    Hartnett, Jim
    Fan, Frank
    Cong, Mei
    Cheng, Jey
    [J]. CANCER RESEARCH, 2017, 77
  • [37] Improved T cell activation bioassays to facilitate the development of bispecific antibodies and engineered T cell immunotherapies
    Stecha, Pete
    Garvin, Denise
    Hartnett, Jim
    Krishnan, Gopal B.
    Fan, Frank
    Cong, Mei
    Cheng, Zhi-jie Jey
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [38] Current nonclinical evaluation of immune-related safety risks for engineered T cell therapies
    Lebrec, H.
    [J]. TOXICOLOGY LETTERS, 2021, 350 : S52 - S52
  • [39] T Cell-based Therapies for Atherosclerosis
    Ketelhuth, Daniel F. J.
    Gistera, Anton
    Johansson, Daniel K.
    Hansson, Goran K.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5850 - 5858
  • [40] Options for T-cell based therapies
    Heslop, HE
    Gottschalk, SM
    Bollard, CM
    Straathof, KCM
    Huls, MH
    Brenner, MK
    Rooney, CM
    [J]. VOX SANGUINIS, 2004, 87 : 230 - 234
12345